Colonic thioguanine pro-drug: Investigation of microbiome and novel host metabolism. (4th March 2018)

• Record Type: Journal Article
• Authors: Florin, Timothy; Movva, Ramya; Begun, Jakob; Duley, John; Oancea, Iulia; Cuív, Páraic Ó.
• Is Part Of: Gut microbes. Volume 9:Isuse 2(2018)
• Page Start: 175
• Page End: 178
• Publication Date: 2018-03-04
• Subjects: colitis -- Harnessing microbial strategies for treatment of human disease -- microbiome -- phagocytosis -- purine salvage -- Role of commensal flora in GI diseases -- Role of gut microbiome in GI disease -- thioguanine; Gastrointestinal system -- Microbiology -- Periodicals; Microbiology -- Periodicals; Intestine, Small -- Periodicals; 616.3
• DOI: 10.1080/19490976.2017.1387343
• Languages: English
• ISSNs: 1949-0984

Abstract

ABSTRACT: Thiopurines are analogues of endogenous purines. They are pro-drugs which require the purine salvage pathway to convert them to the active drug nucleotides (TGN). These drugs are used to maintain clinical remission in patients with inflammatory bowel diseases. In our recent Gut paper, we showed that thioguanine worked quickly to improve colitis in the absence in the host animal of the key guanine salvage enzyme, hypoxanthine-guanine-phosphoribosyltransferase (HPRT). Current evidence favours the proposition that active drug delivery to the host lacking HPRT requires translocation of TGN-loaded bacteria across the inflamed mucosal barrier, and most likely delivery by phagocytosis. Alternatively, the efficacy of thioguanine in treating colitis could be mediated by modulation of the community of the microbiota in the intestine, or there are novel host pathways for conversion of the thioguanine pro-drug to TGN.